Listed investment company Gimv (Euronext: GIMB) is unusual in that it covers every aspect of health – biopharma, medtech and healthcare services – with a focus on mid-caps and a Pan-European approach. It is willing to invest as little as a few million euros up to € 50m and can hold a stake for up to 10-12 years. Active in biopharma since the early eighties, it has also made several investments in healthcare services and medical technologies. So how does Mr. Diels who has worked in VC and private equity for 20 years, view healthcare services as an investment perspective?